TY - JOUR
T1 - Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age
T2 - A Nationwide Real-World Danish Registry Study
AU - Rasmussen, Louise S
AU - Fristrup, Claus W
AU - Jensen, Benny V
AU - Pfeiffer, Per
AU - Weber, Britta
AU - Yilmaz, Mette K
AU - Poulsen, Laurids Ø
AU - Ladekarl, Morten
AU - Østerlind, Kell
AU - Larsen, Jim S
AU - Skuladottir, Halla
AU - Bøgsted, Martin
AU - Falkmer, Ursula G
N1 - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/5/22
Y1 - 2021/5/22
N2 - OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.
AB - OBJECTIVES: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age.METHODS: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more.RESULTS: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35).CONCLUSIONS: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.
KW - age
KW - palliative chemotherapy pattern
KW - pancreatic cancer
KW - registry study
KW - second-line treatment
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85108021068&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001833
DO - 10.1097/MPA.0000000000001833
M3 - Journal article
C2 - 34016900
SN - 0885-3177
VL - 50
SP - 685
EP - 695
JO - Pancreas
JF - Pancreas
IS - 5
ER -